Marker Therapeutics, INC

Marker Therapeutics, Inc. announced that its stockholders approved an amendment to increase authorized common stock from 30 million to 130 million shares at the 2026 Annual Meeting.

Marker Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held on May 1, 2026, establishing a new deadline for shareholder proposals.

Marker Therapeutics announced encouraging clinical data for its lead MT-601 program in lymphoma, alongside Q3 2025 financial results and an extended cash runway.

Marker Therapeutics strengthens its Board of Directors with the appointment of biopharma executive Kathryn Penkus Corzo, effective November 1, 2025.

Marker Therapeutics announced the treatment of the first patient in its Off-the-Shelf (OTS) program for Multi-Antigen Recognizing (MAR)-T cell therapy, showing encouraging preliminary safety data.

Marker Therapeutics announced encouraging Phase 1 APOLLO study results for MT-601 in relapsed lymphoma, showing high objective response rates and a favorable safety profile.

Marker Therapeutics reports a net loss of $3.2 million for Q1 2026 while maintaining a cash runway into Q1 2027.

Marker Therapeutics reported a reduced net loss for the third quarter of 2025, driven by decreased R&D expenses, while also highlighting positive clinical data from its APOLLO study and securing new manufacturing partnerships amidst a 'going concern' warning.

Marker Therapeutics, a clinical-stage immuno-oncology company, reported a significantly wider net loss for Q2 2025 and issued a going concern warning, despite positive early clinical data for its lead therapy MT-601 and recent capital raises.

Marker Therapeutics' Q1 2025 results show a net loss, decreased grant revenue, and ongoing efforts to secure additional funding for clinical trials.

Marker Therapeutics reported its Q3 2024 financial results, highlighting increased grant revenue and reduced operating expenses, while continuing to advance its clinical-stage immuno-oncology programs.

Marker Therapeutics reported its second quarter 2024 financial results, highlighting a decrease in operating expenses and progress in its clinical programs.

Marker Therapeutics' 2024 10-K filing details the company's financial status, clinical trial progress, and strategic shifts, including focusing on MT-601 for lymphoma and pancreatic cancer and MT-401-OTS for AML and MDS.

Marker Therapeutics' 10-K filing highlights its clinical-stage immuno-oncology focus on multiTAA-specific T-cell therapies, a strategic shift in manufacturing, and ongoing clinical trials for lymphoma, pancreatic cancer, and AML.

Marker Therapeutics Director Katharine Knobil received grants of 221,741 stock options as compensation for her service.

Marker Therapeutics director Norman David Eansor received 221,741 stock options for his service in 2024 and 2025 under the company's 2020 Omnibus Stock Ownership Plan.

Marker Therapeutics Director Steve Elms received grants of 221,741 stock options for his service in 2024 and 2025.

Marker Therapeutics Director Kathryn Penkus Corzo was granted 147,611 stock options with an exercise price of $0.9877, vesting over 36 months.

Marker Therapeutics, Inc. CEO Juan Vera was granted 250,000 employee stock options with an exercise price of $0.9877.

Director Steve Elms acquired 30,000 stock options in Marker Therapeutics, Inc. on February 12, 2025, according to a Form 4 filing.

Marker Therapeutics, Inc. will hold its Annual Meeting on May 1, 2026, seeking stockholder approval for a significant increase in authorized common stock and executive compensation.

Marker Therapeutics announces its 2025 Annual Meeting to be held virtually on June 6, 2025, with key proposals including the election of directors, executive compensation approval, and ratification of the company's independent auditor.

Marker Therapeutics announces its Annual Meeting of Stockholders to be held virtually on June 6, 2025, to vote on director elections, executive compensation, and auditor ratification.

Marker Therapeutics is holding a special meeting on March 21, 2025, to seek shareholder approval for the issuance of shares upon the exercise of private placement and pre-funded warrants.

Marker Therapeutics is holding a special meeting to seek stockholder approval for the issuance of shares upon the exercise of warrants, aiming to comply with Nasdaq listing rules and secure funding for its clinical programs.

Marker Therapeutics announces its annual meeting of stockholders to be held virtually on June 6, 2024, to vote on director elections, executive compensation, and auditor ratification.

New Enterprise Associates and its affiliates reported a decrease in their beneficial ownership of Marker Therapeutics, Inc. common stock to 9.9% due to an increase in the total outstanding shares.

John R. Wilson's trust has reduced its beneficial ownership in Marker Therapeutics, Inc. to below 5% through a series of open market sales.

John R. Wilson's trust has reduced its beneficial ownership in Marker Therapeutics, Inc. to 5.10% through recent stock sales.

New Enterprise Associates' beneficial ownership in Marker Therapeutics, Inc. has decreased to 12.6% due to an increase in the company's outstanding common stock.

Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, reported a 9.9% beneficial ownership stake in Marker Therapeutics, Inc., totaling 1,280,952 shares.

Blue Owl Capital Holdings LP has filed an amended Schedule 13G, reporting a 9.99% beneficial ownership stake in Marker Therapeutics, Inc., comprising common stock and exercisable warrants.

Blue Owl Capital Holdings LP has reported a passive 5.18% beneficial ownership stake in Marker Therapeutics, Inc. as of December 31, 2024.

Alyeska Investment Group, L.P., along with its affiliates, has disclosed a passive beneficial ownership of 9.99% in Marker Therapeutics, Inc., totaling 1,069,659 shares as of December 31, 2024.